Myelo Therapeutics Overview
- Year Founded
-
2013
- Status
-
Acquired/Merged
- Employees
-
4
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$18.9M
Myelo Therapeutics General Information
Description
Developer of medical countermeasure drugs designed to treat acute radiation syndrome, reducing radiation-induced myelosuppression after nuclear accidents or attack scenarios. The company develops a small molecule-based oral therapy that is effective in reducing the risk of chemotherapy-induced myelosuppression and radiation in patients across various cancer types and radio-chemotherapy regimens, enabling physicians to improve patient lives.
Contact Information
Website
www.myelotherapeutics.com(Operating Subsidiary)
Corporate Office
- Rheinsberger Strasse 7
- 10115 Berlin
- Germany
Corporate Office
- Rheinsberger Strasse 7
- 10115 Berlin
- Germany
Myelo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 15-Dec-2022 | $18.9M | Completed | Clinical Trials - Phase 2 | ||
| 7. Grant | 04-Jun-2021 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC (Series C) | 26-Jun-2020 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 11-May-2020 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC | 12-Jun-2017 | Completed | Clinical Trials - Phase 2 | |||
| 3. Accelerator/Incubator | 13-Jan-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 15-Dec-2015 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC (Series A) | 13-Apr-2013 | Completed | Startup |
Myelo Therapeutics Comparisons
Industry
Financing
Details
Myelo Therapeutics Competitors (3)
One of Myelo Therapeutics’s 3 competitors is Partner Therapeutics, a Venture Capital-Backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Partner Therapeutics | Venture Capital-Backed | Lexington, MA | ||||
| Amgen | Formerly PE-Backed | Thousand Oaks, CA | ||||
| Emergent BioSolutions | Corporation | Gaithersburg, MD |
Myelo Therapeutics Patents
Myelo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3113478-A1 | Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation | Pending | 25-Sep-2018 | ||
| EP-3856175-A1 | Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation | Pending | 25-Sep-2018 | ||
| US-20210275498-A1 | Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation | Pending | 25-Sep-2018 | ||
| WO-2020064832-A1 | Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation | Inactive | 25-Sep-2018 | ||
| US-20050180953-A1 | Peptides derivatives as an agent inducing cells differentiation and in particular, to their use in antitumor noncytotoxic therapy; melanoma; most preferred compound used in the present invention is 4-[n-(2-imidazol-4-yl)ethyl)carbamoyl]butyric acid (dicarbamine (reg) ) | Active | 28-Feb-2002 | A61K31/195 |
Myelo Therapeutics Signals
Myelo Therapeutics Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Eckert Life Science Accelerator | Accelerator/Incubator | Minority | ||
| IBB Ventures | Venture Capital | Minority | ||
| IDrug | Venture Capital | Minority | ||
| Investitionsbank Berlin | Investment Bank | Minority | ||
| National Institute Of Allergy and Infectious Diseases | Government |
Myelo Therapeutics FAQs
-
When was Myelo Therapeutics founded?
Myelo Therapeutics was founded in 2013.
-
Where is Myelo Therapeutics headquartered?
Myelo Therapeutics is headquartered in Berlin, Germany.
-
What is the size of Myelo Therapeutics?
Myelo Therapeutics has 4 total employees.
-
What industry is Myelo Therapeutics in?
Myelo Therapeutics’s primary industry is Drug Discovery.
-
Is Myelo Therapeutics a private or public company?
Myelo Therapeutics is a Private company.
-
What is the current valuation of Myelo Therapeutics?
The current valuation of Myelo Therapeutics is .
-
What is Myelo Therapeutics’s current revenue?
The current revenue for Myelo Therapeutics is .
-
Who are Myelo Therapeutics’s investors?
Eckert Life Science Accelerator, IBB Ventures, IDrug, Investitionsbank Berlin, and National Institute Of Allergy and Infectious Diseases are 5 of 9 investors who have invested in Myelo Therapeutics.
-
Who are Myelo Therapeutics’s competitors?
Partner Therapeutics, Amgen, and Emergent BioSolutions are competitors of Myelo Therapeutics.
-
When was Myelo Therapeutics acquired?
Myelo Therapeutics was acquired on 15-Dec-2022.
-
Who acquired Myelo Therapeutics?
Myelo Therapeutics was acquired by Eckert & Ziegler.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process